Takeda Pharmaceutical Stock Quote TAK - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

13.21

Bid

Ask

Volume

981,144

13.11 Day's Range 13.23

0.00 52 Week Range 0.00

Market Cap

41.14B

Previous Close

13.11

Open

13.12

Last Trade

13.26

Last Trade Time

Financial Volume

$ 12,935,978

VWAP

13.1846

Average Volume (3m)

Shares Outstanding

3,138,026,928

Dividend Yield

4.63%

PE Ratio

1.07

Earnings Per Share (EPS)

45.91

Revenue

4.28T

Net Profit

144.07B

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geogr... Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Diversified

Website

www.takeda.co.jp

Headquarters

Chuo, Tokyo, Jpn

Founded

1984

Takeda Pharmaceutical Company Ltd is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker TAK. The last closing price for Takeda Pharmaceutical was $13.11. Over the last year, Takeda Pharmaceutical shares have traded in a share price range of $ 0.00 to $ 0.00.

Takeda Pharmaceutical currently has 3,138,026,928 shares outstanding. The market capitalization of Takeda Pharmaceutical is $41.14 billion. Takeda Pharmaceutical has a price to earnings ratio (PE ratio) of 1.07.

Takeda kündigt neue Besetzung der Direktorenposten an

Takeda (TOKYO:4502/NYSE:TAK) hat die neuen Aufgaben der Direktoren bekannt gegeben, die auf der Sitzung des Vorstands und des Prüfungs- und Aufsichtsausschusses im Anschluss an die 148...

Takeda annonce de nouvelles nominations de directeurs

Takeda (TOKYO:4502/NYSE:TAK) a annoncé de nouvelles nominations de directeurs, déterminées lors de la réunion du conseil d’administration et de la réunion du comité d’audit et de surveillance, à...

武田薬品工業: 取締役分掌等の決定について

（ビジネスワイヤ） -- 当社は本日、大阪市内で開催した第148回定時株主総会後の取締役会および監査等委員会において、取締役分掌等を下記のとおり決定しましたのでお知らせします。当社の取締役会は全14名の...

Takeda Announces New Assignments of Directors

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th...

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common and Serious Post-transplant...

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161 Mezagitamab Had a Favorable Safety Profile...

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in...

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for Metastatic Colorectal Cancer (mCRC...

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older Canada...

武田薬品、PNS年次総会にて慢性炎症性脱髄性多発神経炎（CIDP）患者を対象としたHYQVIA®の第3相ADVANCE-CIDP3臨床試験の長期データを発表

CIDPにおける最も長期間な公開臨床試験から、HYQVIAがCIDPの安定した疾病経過を維持するための有効な長期治療の選択肢であるとする好ましい結果が得られた ADVANCE臨床プログラムが、希少な神経免疫疾患患者に...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BENFBeneficient	$ 4.785 (122.56%)	46.48M
SHOTWSafety Shot Inc	$ 0.33 (83.33%)	1.6k
QLGNQualigen Therapeutics Inc	$ 0.28 (59.64%)	244.69M
INVZWInnoviz Technologies Ltd	$ 0.2499 (51.91%)	17.79k
ZAPPZapp Electric Vehicles Group Ltd	$ 4.06 (49.26%)	50.34M
VEVVicinity Motor Corporation	$ 0.391 (-30.67%)	409.44k
SKYESkye Bioscience Inc	$ 5.495 (-26.34%)	354.28k
CLEUChina Liberal Education Holdings Ltd	$ 2.16 (-24.74%)	13.42M
JZXNJiuzi Holdings Inc	$ 2.60 (-23.53%)	57.7k
WHLRWheeler Real Estate Investment Trust Inc	$ 15.02 (-23.01%)	30.36k
MAXNMaxeon Solar Technologies Ltd	$ 0.2378 (36.98%)	520.76M
QLGNQualigen Therapeutics Inc	$ 0.28 (59.64%)	244.69M
NVDANVIDIA Corporation	$ 125.83 (-1.91%)	214.21M
TSLATesla Inc	$ 251.52 (2.08%)	154.53M
SIRISirius XM Holdings Inc	$ 3.715 (5.24%)	121.14M